107 patents
Page 2 of 6
Design
Hand-held electroporation device
23 May 23
Daniel E. Williamson, Andrew Bryan, Kevin Kemmerrer
Filed: 2 Jul 20
Utility
a Tolerable and Minimally Invasive Skin Electroporation Device
11 May 23
A novel electroporation device for the delivery of vaccines that is both effective in generating a protective immune response and tolerable delivery to a subject (or near painless); and also methods of using same device to vaccinate a subject against a variety of infectious diseases and types of cancer in a near painless.
Kate Broderick, Jay McCoy, Stephen V. Kemmerrer, Feng Lin, Rune Kjeken
Filed: 25 Jul 22
Utility
WT1 vaccine
2 May 23
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated WT1 antigen.
David B. Weiner, Jian Yan, Jewell Walters
Filed: 17 Dec 18
Utility
Tert Immunogenic Compositions and Methods of Treatment Using the Same
13 Apr 23
Disclosed herein are compositions comprising optimized consensus TERT antigens and methods for treating cancer and in particular immunogenic compositions that treat and provide protection against tumor.
David Weiner, Jian Yan
Filed: 11 Oct 22
Utility
In Vivo Use of Chondroitinase And/or Hyaluronidase to Enhance Delivery of an Agent
23 Mar 23
Disclosed herein are methods of delivering an agent to a subject.
Trevor Smith, Nina Schommer, Kate Broderick, Bryan Yung, Katherine Schultheis
Filed: 30 Nov 22
Utility
Combination Therapy to Treat Brain Cancer
9 Mar 23
Provided herein are methods of treating brain cancer in a subject, comprising evaluating one or more biological samples from a subject who has brain cancer for the presence of a miRNAs and administering interleukin-12 (IL-12); an immunogenic composition of human telomerase reverse transcriptase (hTERT), Wilms Tumor-1 (WT-1), and prostate specific membrane antigen (PSMA); and an anti-programmed cell death receptor 1 (PD-1) antibody to said subject if the subject has an increased expression level of the mIR-331-3p miRNA or isomiRs thereof and the miR-1537-3p miRNA or isomiRs thereof relative to a control population of subjects.
Amy-Lee Bredlau, Israel Lowy, Jeffrey Skolnik, Jian Yan, Bernadette Ferraro, Jewell Walters, Albert J. Sylvester, III, Kimberly A. Kraynyak, Matthew P. Morrow, Elisabeth Gillespie
Filed: 12 Aug 22
Utility
Tolerable and minimally invasive skin electroporation device
31 Jan 23
A novel electroporation device for the delivery of vaccines that is both effective in generating a protective immune response and tolerable delivery to a subject (or near painless); and also methods of using same device to vaccinate a subject against a variety of infectious diseases and types of cancer in a near painless.
Kate Broderick, Jay McCoy, Stephen V. Kemmerrer, Feng Lin, Rune Kjeken
Filed: 1 Mar 11
Utility
Dna Antibody Constructs and Method of Using Same
26 Jan 23
Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody.
David B. Weiner, Karuppiah Muthumani, Seleeke Flingai, Niranjan Sardesai
Filed: 3 Mar 22
Utility
Side-Port Injection Devices For Use With Electroporation, and Related Systems and Methods
19 Jan 23
An injection device for in vivo delivery of an agent includes a tubular body defining a lumen that extends along a central axis that is oriented along a longitudinal direction.
Paul Fisher, Jay McCoy, Alison A. Generotti, Brenden Ulysses Zounes, Ryne Lucas Contreras
Filed: 30 Jun 22
Utility
Electroporation Device and Injection Apparatus
12 Jan 23
An apparatus is provided for injecting a fluid into body tissue, the apparatus comprising: a hollow needle; and fluid delivery means, wherein the apparatus is adapted to actuate the fluid delivery means in use so as to automatically inject fluid into body tissue during insertion of the needle into the said body tissue.
Iacob Mathiesen, Torunn E. Tjelle, Knut Arvid Sorensen Rekdahl, Bjorn David-Andersen
Filed: 19 Sep 22
Utility
Cancer Vaccines and Methods of Treatment Using the Same
12 Jan 23
Disclosed herein are compositions and methods for treating cancer and in particular vaccines that treat and provide protection against tumor growth.
David B. Weiner, Jian Yan, Karuppiah Muthumani, Jewell Walters
Filed: 20 Jul 22
Utility
Improved Vaccines for Recurrent Respiratory Papillomatosis and Methods for Using the Same
5 Jan 23
The use of anti-HPV immunogens and nucleic acid molecules that encode them for the treatment and prevention of RRP are disclosed.
David B. Weiner, Jian Yan
Filed: 26 Oct 20
Utility
Electrode Arrays For Electroporation, and Related Systems and Methods
5 Jan 23
An electrode array for use with an electroporation device includes a support member having a top surface and a bottom surface and defines a plurality of injection channels extending from the top surface to the bottom surface.
Jay McCoy, Paul Fisher, SR.
Filed: 30 Jun 22
Utility
Device and Method for Single-needle In Vivo Electroporation
5 Jan 23
Described is a device and method for administration of molecules to tissue in vivo for various medical applications, the device comprising a single hypodermic injection needle and at least two spaced elongate electrodes which provide for the ability, when the needle is inserted into tissue, such as skin or muscle, to pulse tissue with a non-uniform electric field sufficient to cause reversible poration of cells lying along or in close proximity to the track made by the needle upon its insertion into said tissue.
Rune KJEKEN, Iacob MATHIESEN, Torunn Elisabeth TJELLE, George MCHUGH
Filed: 29 Apr 22
Utility
Vaccines Against Coronavirus and Methods of Use
24 Nov 22
Provided herein are methods of inducing an immune response against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) in a subject in need thereof by administering an immunogenic composition to the subject, wherein the subject exhibits: an increase in antigen-specific cellular immune response as measured by Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) assay relative to baseline; and/or an increase in neutralizing antibody response as measured by a pseudovirus neutralizing assay relative to baseline.
Jian Yan, Kate Broderick, David Weiner, Kar Muthumani, Ami Patel
Filed: 5 May 22
Utility
Immunogenic Compositions Against SARS-COV-2 Variants and Their Methods of Use
27 Oct 22
Disclosed herein are nucleic acid molecules encoding a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a SARS-CoV-2 infection in a subject.
Charles Reed, Stephanie Ramos, Trevor Smith, Maria Yang, Richa Kalia, Kate Broderick
Filed: 22 Apr 22
Utility
Methods of Inducing Immune Response Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern
20 Oct 22
Disclosed herein are methods of administering and uses of a plasmid encoding residues 19-1279 of SEQ ID NO: 1, a plasmid comprising nucleotides 55-3837 of SEQ ID NO: 2, pGX9501, INO-4800 drug product, or a biosimilar thereof to induce an immune response against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) variant B.1.351, SARS-CoV-2 variant B.1.1.7, SARS-CoV-2 variant P.1, SARS-CoV-2 variant B.1.617.1, SARS-CoV-2 variant B.1.617.2, or SARS-CoV-2 variant B.1.1.529.
Trevor Smith, Stephanie Ramos, Viviane Machado De Mello Andrade
Filed: 13 Apr 22
Utility
Electroporation device and injection apparatus
18 Oct 22
An apparatus is provided for injecting a fluid into body tissue, the apparatus comprising: a hollow needle; and fluid delivery means, wherein the apparatus is adapted to actuate the fluid delivery means in use so as to automatically inject fluid into body tissue during insertion of the needle into the said body tissue.
Iacob Mathiesen, Torunn E. Tjelle, Knut Arvid Sorensen Rekdahl, Bjorn David-Andersen
Filed: 5 Aug 19
Utility
TERT immunogenic compositions and methods of treatment using the same
11 Oct 22
Disclosed herein are compositions comprising optimized consensus TERT antigens and methods for treating cancer and in particular immunogenic compositions that treat and provide protection against tumor.
David Weiner, Jian Yan
Filed: 29 Sep 17
Utility
Cancer Vaccines Targeting LEMD1 and Uses Thereof
25 Aug 22
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated consensus LEMD1 antigen.
Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
Filed: 25 Apr 22